Press Releases

DAY HI:
DAY LOW:
VOLUME:

Copyright West LLC. Minimum 15 minutes delayed.

Press Releases

Date Title Format
Feb 12, 2015
Results support the safety and efficacy of high-dose Captisol-enabled (CE)-Melphalan as a high-dose conditioning treatment prior to autologous hematopoietic stem cell transplantation (AHCT) in patients with multiple myeloma (MM). Overall Response Rate improved from 79% at study entry to 95% after
Dec 26, 2014
Approval is being sought for use as a high-dose conditioning treatment prior to stem cell transplantation in multiple myeloma and for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. The Company expects FDA review to take approximately 10 months.
Dec 05, 2014
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced key presentations of clinical and scientific data related to its
Nov 12, 2014
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial
Nov 06, 2014
Total product sales for the three months ended September 30, 2014 increased 15.6% to $47.9 million from $41.4 million in the same period last year. Non-GAAP diluted EPS was $0.08 , and GAAP EPS was ( $0.18 ). Spectrum's fifth oncology drug, Beleodaq® (belinostat) for Injection was approved by the
Oct 30, 2014
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to
Sep 18, 2014
Spectrum receives a 19.99% stake (pre-transaction) in CASI, a NASDAQ-listed, oncology-focused Company with expertise and focus on markets in China and a $1.5 million promissory note HENDERSON, Nev. & ROCKVILLE, Md. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc.
Sep 16, 2014
A new Beleodaq patent (No. 8835501) issued with patent term adjustment Beleodaq launched in July 2014 with Spectrum's existing sales force HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development
Sep 09, 2014
SPI-2012 met the primary endpoint in a multicenter Phase 2 study that evaluated the effectiveness and safety of SPI-2012 compared to a standard dose of pegfilgrastim. The Company plans to meet with the FDA to discuss its Phase 3 design before year-end and submit Phase 2 results for presentation at
Sep 02, 2014
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial
Aug 07, 2014
Total product sales for the three months ended June 30, 2014 were $46.9 million , compared to $32.2 million in the same period last year, an increase of 45%. Sequential quarter sales were up 17%, driven primarily by end-user product demand. Non-GAAP diluted EPS was $0.09 , and GAAP EPS was ( $0.06
Jul 31, 2014
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to
Jul 07, 2014
Early Action before PDUFA date of August 9, 2014 follows Priority Review Beleodaq to be launched through Spectrum's existing sales force Beleodaq is expected to be available to patients in less than 3 weeks HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a
May 30, 2014
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial
May 28, 2014
SPI-2012, is a Long-Acting GCSF that utilizes a proprietary platform technology, LAPSCOVERY™, designed to the maximize pharmacological activity of GCSF with potential advantages relating to more rapid and potent granulocyte recovery compared to pegylated filgrastim.
May 09, 2014
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial
May 08, 2014
Total product sales for the three months ended March 31, 2014 were $40.1 million , compared to $29.3 million in the same period last year, an increase of 37%. Non-GAAP EPS was $0.01 , and GAAP EPS was ( $0.44 ). Spectrum expects a decision on the NDA approval of Beleodaq™ by the FDA's decision date
May 01, 2014
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to
Apr 23, 2014
CE Melphalan is being developed as a novel version of the well-established conditioning treatment in autologous transplant for patients with multiple myeloma. CE Melphalan does not contain propylene glycol, an ingredient in currently available products which has been associated with renal and
Apr 21, 2014
Joseph Turgeon has more than 30 years of experience in the biotech industry, including 22 years at Amgen; until recently was Spectrum's Chief Commercial Officer Thomas Riga promoted to Senior Vice President and Chief Commercial Officer; Tom has more than 15 years' experience in the biotech
Displaying 141 - 160 of 777